Services / endocrinology weight loss

Semaglutide Weight Loss Program in Chicago

Semaglutide is an FDA-approved GLP-1 receptor agonist that has revolutionized medical weight loss. Originally developed for type 2 diabetes, Semaglutide (known by brand names Ozempic and Wegovy) has shown remarkable efficacy for weight management -- with the STEP 1 trial showing an average weight loss of about 15% of body weight at 68 weeks. At Stonewood Health, our medically supervised Semaglutide programs include comprehensive metabolic testing, Dosing set from your labs, nutritional guidance, and ongoing monitoring for safe, sustainable results.

Book a visit

What it helps with

Average weight loss of about 15% of body weight in the STEP 1 trial

Reduces appetite and food cravings

Improves metabolic health markers

Once-weekly injection

Improves blood sugar and A1C levels

Reduces cardiovascular risk factors

Sustainable weight management with lifestyle support

What happens

01

Initial consultation and health assessment

02

Comprehensive metabolic and blood panel

03

BMI, body composition, and baseline measurements

04

Begin Semaglutide at starting dose with gradual titration

05

Monthly check-ins with weight and metabolic monitoring

06

Nutritional counseling and lifestyle support

07

Ongoing dose management for best results

Who it is for

Semaglutide is ideal for adults with a BMI of 27+ with weight-related conditions, or BMI 30+ seeking medical weight management.

Adults with BMI 30+ (obesity)

Adults with BMI 27+ and weight-related health conditions

Those who haven't achieved lasting results with diet and exercise alone

Patients seeking an FDA-approved, evidence-based solution

Those wanting to reduce metabolic disease risk factors

Questions

In the STEP 1 trial, average weight loss was 14.9% of body weight at 68 weeks, against 2.4% on placebo. About half of participants lost at least 15%, and about a third lost at least 20%. Individual results vary based on starting weight, adherence, and lifestyle factors.